Assessing the Psychedelic "After-Glow" in Ayahuasca Users : Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities by Riba Serrano, Jordi et al.
Received: October 4, 2016; Revised: May 10, 2017; Accepted: May 17, 2017
© The Author 2017. Published by Oxford University Press on behalf of CINP.
International Journal of Neuropsychopharmacology (2017) 20(9): 698–711
doi:10.1093/ijnp/pyx036
Advance Access Publication: June 13, 2017
Regular Research Article
698
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, 
provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
regular research article
Assessing the Psychedelic “After-Glow” in Ayahuasca 
Users: Post-Acute Neurometabolic and Functional 
Connectivity Changes Are Associated with Enhanced 
Mindfulness Capacities
Frederic Sampedro, MSc; Mario de la Fuente Revenga, PhD;  
Marta Valle, PhD; Natalia Roberto, MSc; Elisabet Domínguez-Clavé, MSc; 
Matilde Elices, PhD; Luís Eduardo Luna, PhD; José Alexandre S. Crippa, PhD; 
Jaime E. C. Hallak, PhD; Draulio B. de Araujo, PhD; Pablo Friedlander, MSc; 
Steven A. Barker, PhD; Enrique Álvarez, PhD; Joaquim Soler, PhD;  
Juan C. Pascual, PhD; Amanda Feilding, MSc; Jordi Riba, PhD
School of Medicine, Autonomous University of Barcelona, Barcelona, Spain (Mr Sampedro); Human 
Neuropsychopharmacology Research Group, Sant Pau Institute of Biomedical Research, Barcelona, Spain 
(Dr de la Fuente Revenga, Ms Roberto, and Dr Riba); Pharmacokinetic and Pharmacodynamic Modelling and 
Simulation, Sant Pau Institute of Biomedical Research, Barcelona, Spain (Dr Valle); Centre d’Investigació de 
Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Drs 
Valle and Riba); Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Spain (Drs Valle, 
Elices, Álvarez, Soler, Pascual, and Riba); Department of Pharmacology and Therapeutics, Autonomous 
University of Barcelona, Barcelona, Spain (Dr Valle); Department of Psychiatry, Hospital de la Santa Creu i 
Sant Pau, Barcelona, Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, Soler, and Pascual); Department 
of Psychiatry and Forensic Medicine, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, 
Spain (Ms Domínguez-Clavé and Drs Elices, Álvarez, and Pascual); Research Center for the Study of 
Psychointegrator Plants, Visionary Art and Consciousness, Florianópolis, Santa Catarina, Brazil (Dr Luna); 
Department of Neuroscience and Behavior, Medical School of Ribeirão Preto, University of São Paulo, São 
Paulo, Brazil and National Institute for Translational Medicine, Ribeirão Preto, Brazil (Drs Crippa and Hallak); 
Brain Institute/Hospital Universitario Onofre Lopes, Natal, Brazil (Dr de Araujo); The Beckley Foundation, 
Beckley Park, Oxford, United Kingdom (Mr Friedlander and Mrs Feilding); Department of Comparative 
Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Skip Bertman Drive at 
River Road, Baton Rouge, Louisiana (Dr Barker); Department of Clinical and Health Psychology, School of 
Psychology, Autonomous University of Barcelona, Barcelona, Spain (Dr Soler).
Correspondence: Jordi Riba, PhD, Human Neuropsychopharmacology Research Group, IIB-Sant Pau.C/Sant Antoni María Claret 167, 08025, Barcelona, 
Spain (jriba@santpau.cat).
Sampedro et al. | 699
Abstract
Background: Ayahuasca is a plant tea containing the psychedelic 5-HT2A agonist N,N-dimethyltryptamine and harmala 
monoamine-oxidase inhibitors. Acute administration leads to neurophysiological modifications in brain regions of the 
default mode network, purportedly through a glutamatergic mechanism. Post-acutely, ayahuasca potentiates mindfulness 
capacities in volunteers and induces rapid and sustained antidepressant effects in treatment-resistant patients. However, 
the mechanisms underlying these fast and maintained effects are poorly understood. Here, we investigated in an open-label 
uncontrolled study in 16 healthy volunteers ayahuasca-induced post-acute neurometabolic and connectivity modifications 
and their association with mindfulness measures.
Methods: Using 1H-magnetic resonance spectroscopy and functional connectivity, we compared baseline and post-acute 
neurometabolites and seed-to-voxel connectivity in the posterior and anterior cingulate cortex after a single ayahuasca dose.
Results: Magnetic resonance spectroscopy showed post-acute reductions in glutamate+glutamine, creatine, and 
N-acetylaspartate+N-acetylaspartylglutamate in the posterior cingulate cortex. Connectivity was increased between the 
posterior cingulate cortex and the anterior cingulate cortex, and between the anterior cingulate cortex and limbic structures 
in the right medial temporal lobe. Glutamate+glutamine reductions correlated with increases in the “nonjudging” subscale of 
the Five Facets Mindfulness Questionnaire. Increased anterior cingulate cortex-medial temporal lobe connectivity correlated 
with increased scores on the self-compassion questionnaire. Post-acute neural changes predicted sustained elevations in 
nonjudging 2 months later.
Conclusions: These results support the involvement of glutamate neurotransmission in the effects of psychedelics in humans. 
They further suggest that neurometabolic changes in the posterior cingulate cortex, a key region within the default mode 
network, and increased connectivity between the anterior cingulate cortex and medial temporal lobe structures involved in 
emotion and memory potentially underlie the post-acute psychological effects of ayahuasca.
Keywords: ayahuasca, psychedelic after-effects, magnetic resonance imaging, mindfulness, human
Introduction
Psychedelics are the object of renewed interest as potential 
therapeutic tools in psychiatry (Sessa, 2005; Vollenweider and 
Kometer, 2010; Grob et  al., 2011). Among these substances is 
ayahuasca, an Amazonian psychoactive beverage typically 
obtained from the plants Banisteriopsis caapi and Psychotria 
viridis. The ayahuasca tea contains a combination of the psy-
chedelic indole N,N-dimethyltryptamine (DMT) from P. viridis, 
and β-carboline (harmala) alkaloids with monoamine-oxidase-
inhibiting properties from B. caapi (McKenna et al., 1984). DMT is 
a classical serotonergic psychedelic that stimulates the 5-HT2A 
receptor (Carbonaro et al., 2015). Agonism at this level by DMT 
and other psychedelics recruits glutamatergic neurotrans-
mission (Carbonaro et  al., 2015), induces neuronal excitatory 
effects (Kłodzinska et al., 2002), and increases glutamate release 
(Scruggs et  al., 2003; Muschamp et  al., 2004). However, unlike 
psilocybin or LSD, DMT is orally inactive due to extensive deg-
radation by monoamine-oxidase (Riba et al., 2015). Interestingly, 
the presence of β-carbolines in the ayahuasca tea inhibits DMT 
metabolism, allowing for psychoactive effects after oral intake 
(Riba et  al., 2003). Additionally, DMT shows neuroprotective 
effects mediated through interaction with the sigma-1 receptor 
(Szabo et al., 2016).
Interest in the general pharmacology and therapeutic 
properties of ayahuasca has greatly increased in recent years 
(Domínguez-Clavé et al., 2016). Acute administration to healthy 
volunteers induces a transient introspective state character-
ized by dream-like visions with eyes closed, recollection of per-
sonal memories, and intense emotion (Riba et al., 2001, 2003). 
Neurophysiological studies show a suppression of the inhibitory 
alpha rhythm in the occipital and parietal cortex, including the 
posterior cingulate cortex (PCC) (Schenberg et al., 2015; Valle et 
al., 2016), a key node of the default mode network (DMN) with 
a prominent role in self-reflection and consciousness (Vogt and 
Laureys, 2005). Furthermore, decreased activity for the most 
part of the DMN and reduced connectivity of the PCC have been 
observed during the acute effects of ayahuasca (Palhano-Fontes 
et al., 2015). On the other hand, radiotracer data shows increased 
blood flow in the anterior cingulate cortex (ACC) and in the 
insula, amygdala, and hippocampus, brain areas involved in cog-
nitive control, emotion, and memory (Riba et al., 2006). Recently, 
Significance Statement
Psychedelics are intriguing drugs that induce transient but intense modifications in perception, emotion, and cognition. Despite 
human use dating back millennia, their mechanism of action is still poorly understood. Recent research in patients has shown 
that ayahuasca, a plant psychedelic used traditionally in the Amazon for religious and medicinal purposes, exerts rapid and 
potent antidepressant effects in treatment-resistant patients. These beneficial effects are observed after a single dose and 
intriguingly persist for weeks, long after the immediate acute effects have disappeared. Here we demonstrate using 2 neuroim-
aging techniques that during the post-acute phase, that is within 24 hours after intake, ayahuasca leads to metabolic and con-
nectivity changes in the brain. These changes are associated with enhanced psychological capacities that are beneficial in the 
therapeutic context. These findings provide a biological basis for the post-acute or “after-glow” stage of psychedelic effects, and 
contribute to elucidate the therapeutic mechanisms of these substances.
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ayahuasca was found to induce post-acute increases in “decen-
tering” ability, that is, the capacity to observe one’s thoughts 
and emotions in a detached manner, and to reduce automatic 
negative judgmental attitudes and inner reactivity (Soler et al., 
2016). It thus enhanced a series of “mindfulness” capacities tra-
ditionally cultivated by meditation schools and that are known 
to be impaired in many forms of psychopathology (Soler et al., 
2014b). In a subsequent review, the authors postulated that the 
mindfulness-enhancing properties of ayahuasca could be used 
in a therapeutic context to facilitate emotional reprocessing in 
patients with depression, addiction, and personality disorders 
(Domínguez-Clavé et al., 2016).
In line with the above, 2 recent open-label uncontrolled clini-
cal studies have found rapid reductions in psychopathology after 
administration of single ayahuasca doses to depressed patients. 
Remarkably, antidepressant effects appeared within hours after 
dosing and were maintained for 3 weeks (Osório et  al., 2015; 
Sanches et al., 2016). Analogous improvements have also been 
observed after psilocybin (Carhart-Harris et  al., 2016b). In all 
cases, sustained antidepressant effects were in sharp contrast 
with the much shorter duration of the acute psychedelic state. 
This disparity of time courses suggests that 5-HT2A stimulation 
leads to persistent effects beyond the time frame of the acute 
inebriation. In fact, early researchers coined the term “after-glow” 
to designate a positive post-acute phase of psychedelic drug 
effects characterized by elevated mood and openness (Pahnke 
et al., 1970). This post-acute phase has been reported to extend 
between 6 and 8 weeks after the acute psychedelic effects and 
characterized as a window of opportunity for therapeutic inter-
vention (Halpern, 1996; Winkelman, 2014). Recent clinical studies 
have described persisting positive after-effects following psilocy-
bin and LSD (Griffiths et al., 2008; Lebedev et al., 2016).
Here, we investigated the neural correlates of the psychedelic 
“after-glow” in healthy volunteers to improve our understanding 
of the neural mechanisms potentially involved in the rapid and 
sustained therapeutic effects observed in patients. Using 2 differ-
ent neuroimaging techniques, we assessed post-acute neuromet-
abolic and connectivity changes induced by ayahuasca in healthy 
volunteers. Our study focused on the PCC and the ACC, 2 brain 
regions that have consistently been identified as targets of psych-
edelics (Carhart-Harris et al., 2012, 2016a; Palhano-Fontes et al., 
2015; Valle et  al., 2016). We postulated 3 hypotheses. First, that 
excitatory effects in PCC and ACC during acute ayahuasca would 
lead to measurable decreases of glutamate-glutamine and energy 
metabolites in the post-acute phase. Second, that neurometabolic 
changes would parallel enhanced connectivity between the PCC 
and the ACC by decreasing the normal pattern of anticorrelated 
brain activity existing between these brain regions. Third, that the 
measured neurometabolic and connectivity changes would cor-
relate with increased mindfulness capacities in the immediate 
post-acute phase and at follow-up 2 months later.
Materials and Methods
Ethics
The study was approved by the Ethics Committee at Hospital 
de Sant Pau (Barcelona, Spain). All participants provided written 
informed consent to participate in the study.
Participants
The study included 16 healthy volunteers (6 females) with 
prior experience with ayahuasca. Exclusion criteria included a 
current or past history of psychiatric disorders, alcohol or other 
substance dependence, evidence of significant illness, and preg-
nancy. Detailed information on the recruitment procedure and 
the characteristics of study participants is provided in the sup-
plementary file.
Drug
A single ayahuasca batch was used in the study. All participants 
ingested ayahuasca from this single batch, so alkaloid concen-
trations were the same for all subjects. The ayahuasca used 
was analyzed and the total volume ingested by each participant 
was recorded. Alkaloid concentrations were determined using 
a previously described method implementing liquid chroma-
tography-electrospray ionization-tandem mass spectrometry 
(McIlhenny et al., 2009). Based on the analysis, the ayahuasca 
used in the session contained 0.3  mg/mL DMT, 0.86  mg/mL 
harmine, 0.17 mg/mL tetrahydroharmine, and 0.04 mg/mL har-
maline. Participants took a mean ± SD volume of ayahuasca 
during the session of 148 ± 29 mL. Thus, the mean ± SD alkaloid 
amounts ingested were: 45 ± 9 mg DMT, 126 ± 25 mg harmine, 
26 ± 5 mg tetrahydroharmine, and 5 ± 1 mg harmaline. For a 
70-kg person, the dose would be equivalent to 0.64 mg DMT/
kg, within the range found to be psychoactive in laboratory 
studies by our group (Riba et  al., 2001, 2003). In the present 
study, we conducted post- vs. pre-ayahuasca comparisons of 
the dependent variables. No placebo was used in the present 
investigation.
Study Design
Participants were assessed twice in an MRI scanner. The first 
measurement was conducted in the 24 h prior to an ayahuasca 
session. The baseline assessment included the acquisition of 
anatomical high-resolution T1 images, 1H-MR spectroscopy data, 
and resting-state BOLD activity. Participants also completed 3 
mindfulness questionnaires before the first scan. The post-acute 
assessment was conducted in the 24 hours after the ayahuasca 
session. It involved again obtaining structural T1 images, 1H-MR 
spectroscopy, resting-state BOLD data, and the same mindful-
ness questionnaires. The second MRI assessment was conducted 
for each participant at approximately the same time of the day 
as the first assessment, with a variation of about 30 minutes. 
The meals ingested by participants were equivalent on each 
assessment day. Participants were asked to fill out the mindful-
ness questionnaires indicating how they felt during the post-
acute stage. Additionally, participants were asked to fill out the 
Hallucinogen Rating Scale, a subjective effects questionnaire, to 
indicate retrospectively how they had felt during the acute psy-
chedelic phase. Two months later, a follow-up was conducted. 
Participants were requested to fill out again the mindfulness 
questionnaires they had been administered at baseline and in 
the post-acute phase.
Image Acquisition and Analysis
Images were acquired on a 3T Siemens Magneto TIM Trio scan-
ner using a 32-channel phased-array head coil. The assessment 
protocol involved obtaining: (1) high resolution T1 structural 
images; (2) spectroscopy data in 3 volumes of interest (VOIs); 
and (3) resting state BOLD data for functional connectivity anal-
ysis. Each measurement is described briefly below and in depth 
in the supplementary information.
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MR Spectroscopy: Neurometabolite Assessment
Single voxel spectra were obtained from 3 VOIs placed in the 
PCC, ACC, and cerebellum, as shown in Figure 1 (top panel) for 
one of the participants.
Metabolite concentrations were quantified for total cre-
atine plus phosphocreatine (Cr), total choline containing 
compounds (glycerophosphocholine plus phosphocholine; 
Cho), inositol (Ins), combined glutamate plus glutamine (Glx), 
and total N-acetylaspartate plus N-acetylaspartylglutamate 
(NAA-NAAG). We used absolute metabolite levels, since ratios 
with creatine have been found to be a potential confounding 
factor and the source of increased variability (Li et al., 2003). 
See the supplementary materials for further details on VOI 
placement, quality assurance of measurements, and tissue 
corrections.
The obtained millimolar (mM) metabolite concentrations 
were compared at each VOI using repeated-measures ANOVA 
with ayahuasca intake (post- vs. pre-ayahuasca) and metabolite 
type as factors (Cr, Cho, Ins, Glx, and NAA-NAAG). When a sig-
nificant effect of ayahuasca intake or the interaction ayahuasca 
intake by metabolite type was found, pair-wise comparisons 
were conducted using Student’s t tests. Results were considered 
significant for P < .05. Statistical results are presented in tabu-
lated form showing uncorrected P values and values corrected 
for multiple comparisons using the false discovery rate (FDR). 
Effect size is provided using Cohen’s d (see supplementary file 
for details).
Resting State BOLD Signal Acquisition and Functional 
Connectivity Analysis
Resting state functional images were collected using a 7-min-
ute sequence during which participants stayed awake with 
eyes closed. The functional connectivity analysis was con-
ducted using the CONN software (Whitfield-Gabrieli and Nieto-
Castanon, 2012). The analysis included several preprocessing 
steps (see supplementary file), followed by a first-level statis-
tical analysis calculating seed-to-voxel connectivity maps for 
each subject and condition (pre-ayahuasca and post-acute). 
Individual z-maps were used in the subsequent random-effects 
second-level analysis to assess drug-induced changes in con-
nectivity (post- vs. pre-ayahuasca intake) using paired-samples 
Student’s t tests.
Post-acute ayahuasca-induced changes in seed-to-voxel 
connectivity were assessed using 3 spherical seeds with 10-mm 
radius. The first was placed in the PCC at MNI coordinates x = 0, 
y = -56, z = 28, based on previously published data (Whitfield-
Gabrieli and Nieto-Castanon, 2012). The 2 additional seeds were 
placed in the ACC. The first seed was placed in the dorsal ACC 
(dACC) at MNI coordinates x = 5, y = 14, z = 42, over BA 32, a sub-
region of the ACC involved in executive top-down control, and 
positive task activation (Kelly et al., 2009). A second more ros-
tral seed (here denoted as “superior rostral ACC” or srACC) was 
placed at MNI coordinates x = 0, y = 15, z = 30) in BA 24 (Dixon 
et al., 2014). This subregion of the ACC has extensive connectiv-
ity with limbic structure in the medial temporal lobe (Vogt, BA, 
Figure 1. Location of the 1H-MRS voxels (top) and a representative spectrum (bottom). The top panel shows sagittal views of voxel placement over the anterior cingulate 
(left), posterior cingulate (center), and cerebellum (right). The dimensions of the respective voxels were: 25 x 25 x 25 mm3 in the anterior cingulate cortex (ACC) and 
posterior cingulate cortex (PCC) and 20 x 40 x 20 mm3 in the cerebellum.
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2009) and has been found to be hypoactive in depressed patients 
(Fales et al., 2008).
The significance maps obtained in the second-level analy-
sis were corrected for multiple comparisons at the cluster level 
using the family wise error correction (FWE). Significance level 
was set at FWE < 0.05 for a spatial extension of at least 20 con-
tinuous voxels. Further details on image acquisition and analy-
sis can be found in the supplementary file.
Mindfulness Measures
Assessment Instruments and Statistical Analysis
Scores on mindfulness facets were assessed before and after 
ayahuasca intake using the Spanish versions of the follow-
ing instruments: (1) the Five Facet Mindfulness Questionnaire 
(FFMQ) (Cebolla et al., 2012); (2) the Experiences Questionnaire 
(EQ) (Soler et  al., 2014b); and (3) the short version of the Self-
Compassion (SC) questionnaire (Garcia-Campayo et  al., 2014). 
Additionally, the Mindsens Composite Index was calculated 
with items from the FFMQ and EQ. This index is most sen-
sitive to meditation practice and accurately discriminates 
between meditators and nonmeditators (Soler et al., 2014a). The 
Mindsens index was used to assess to what extent the changes 
induced by ayahuasca were comparable with those induced by 
meditation practice.
Scores on mindfulness facets (FFMQ, EQ, and SC) were 
obtained before and after ayahuasca intake. Baseline assess-
ment was conducted in the 24 hours prior to ayahuasca intake, 
and the second was conducted within the 24 hours after intake, 
before going into the MRI scanner. Participants were contacted 
by email 2  months after participation to conduct a follow-up 
assessment. Fourteen of the 16 participants responded and 
returned the completed questionnaires. This follow-up analysis 
had consequently less power to detect changes and should be 
thus considered exploratory. In all instances, participants were 
asked to fill out the questionnaires indicating how they felt at 
the moment of completion. Further details on the instruments 
used are provided in the supplementary file.
Ayahuasca-induced changes in mindfulness measures were 
assessed using paired-samples t tests. Scores at follow-up were 
compared with pre-ayahuasca values. Results were considered 
significant for P < .05. Statistical results are presented visually as 
bar graphs and in tabulated form (supplementary material). The 
supplementary table shows uncorrected P values and values 
corrected for multiple comparisons using the FDR.
Acute Subjective Effects
Assessment Instruments and Statistical Analysis
To establish that participants had experienced psychoactive 
effects during the acute phase, the intensity of the psychedelic 
effects during the acute inebriation were retrospectively assessed 
using a Spanish version of the Hallucinogen Rating Scale (HRS). 
The HRS was administered only once, in the course of the post-
ayahuasca assessment, before the MRI scan. Participants were 
requested to fill out the questionnaire indicating how they had 
felt during the acute effects of ayahuasca.
To statistically verify that the dose ingested was indeed psy-
choactive, scores obtained in the 6 HRS subscales (see supplemen-
tary materials) were compared with scores obtained previously 
in a laboratory study from a sample of 12 healthy volunteers 
who received a placebo and an ayahuasca dose equivalent to 
0.75  mg DMT/kg body weight (Valle et  al., 2016). The statisti-
cal comparison was carried out using independent-samples 
Student’s t tests. Results were considered significant for P < .05. 
Results are shown in a figure with significance symbols denoting 
P values after multiple comparisons correction using the FDR.
Exploratory Correlation Analysis
Correlation analyses were conducted to explore potential asso-
ciations between neurometabolic and functional connectivity 
changes on the one hand and scores on subjective effects meas-
ures and mindfulness questionnaires on the other. In all calcula-
tions, difference values (post- minus pre-ayahuasca) were used. 
For connectivity data, the difference in z-values (post- minus 
pre-ayahuasca) was calculated for clusters showing ayahuasca-
induced significant changes in connectivity in the paired-sam-
ples comparison between normalized statistical maps (post- vs. 
pre-ayahuasca). Correlations with mindfulness measures at 
follow-up were calculated using the difference values between 
follow-up scores and pre-ayahuasca values. Correlations were 
considered significant for P < .05. Given the exploratory nature 
of this analysis, we did not implement corrections for multiple 
comparisons, and results should be interpreted with caution.
Results
All 16 participants completed the baseline and post-acute 
assessments. There were no drop-outs in the study.
MR Spectroscopy: Neurometabolite Assessment
Average metabolite concentrations in the baseline and post-
acute assessments in the 3 VOIs examined are shown in Table 1. 
Data from several participants were below the signal-to-noise 
threshold either in the pre- or post-ayahuasca assessment and 
had to be excluded from further analysis. Usable data for Glx 
assessment in the PCC were obtained from 12 participants, 13 
for the ACC, and 11 for the cerebellum. Inositol in the PCC could 
be adequately measured in 13 participants. All other metabo-
lites could be quantified in the PCC, ACC, and cerebellum in 14 
participants.
In the PCC VOI, the 2-factor repeated-measures ANOVA 
showed a significant effect of metabolite type [F(4,44) = 761, 
P < .001], a trend for ayahuasca intake [F(1,12) = 3.88, P = .075], and 
significant interaction between ayahuasca intake and metabo-
lite type [F(4,44) = 4.11, P < .023]. As shown in Table 1, the pair-wise 
comparisons showed significant decreases in Cr and NAA-NAAG 
levels in the post-intake assessment. Glx levels were signifi-
cantly decreased in the initial t test (P = .041), but this effect was 
marginally significant following the FDR correction (P = .068). Ins 
and Cho concentrations remained unchanged.
In the ACC VOI, only an effect of metabolite type was 
observed [F(4,48) = 997, P < .001], but not effect of ayahuasca intake 
[F(1,12) = 0.32, P = .860] or the interaction [F(4,48) = 0.55, P = .606].
In the cerebellum VOI, the ANOVA yielded a significant effect 
of metabolite type [F(4,44) = 321, P < .001], but no effects of aya-
huasca intake [F(1,11) = 1.44, P = .255] or the interaction between 
intake and metabolite type [F(4,44) = 0.54, P = .632]. Mean metabo-
lite concentrations at baseline assessment and in the post-acute 
phase for these 3 VOIs are also shown in Table 1.
Functional Connectivity Assessment
Usable pre-ayahuasca and post-acute resting-state functional 
connectivity scans were obtained from all 16 participants. No 
subjects had to be eliminated due to excessive movement (see 
the supplementary information file for further details). Figure 2 
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shows brain maps corresponding to the analysis of functional 
connectivity between the PCC seed (0, -56, 28) and the rest of 
the brain. The top panels display the results of the first-level 
statistical analysis separately for the pre-ayahuasca and the 
post-acute assessments. The bottom panels display the results 
of the second-level comparison between post-acute vs. pre-aya-
huasca correlation maps. The statistical maps are shown cor-
rected for multiple comparisons at the cluster level (FWE P < .05). 
Table 1. Neurometabolite Levels at Baseline and in the 24 Hours after Ayahuasca Intake for the 3 Examined Regions of Interest
Brain Region and Metabolite Baseline Post-Ayahuasca n df t Value P Value P FDR Cohen’ d
PCC
Inositol 8.26 (1.06) 8.32 (0.95) 13 12 -0.24 0.817 0.817 –
Glx 6.60 (0.64) 6.25 (0.57) 12 11 2.31 0.041** 0.068* 0.67
Cr 8.88 (0.50) 8.61 (0.46) 14 13 3.03 0.010** 0.043** 0.81
Cho 1.79 (0.19) 1.77 (0.18) 14 13 0.83 0.421 0.526 –
NAA-NAAG 12.83 (0.70) 12.03 (0.93) 14 13 2.74 0.017** 0.043** 0.73
ACC
Inositol 8.75 (0.82) 8.57 (0.79) 14 – – – – –
Glx 5.38 (0.39) 5.51 (0.50) 13 – – – – –
Cr 8.39 (0.40) 8.40 (0.44) 14 – – – – –
Cho 2.22 (0.20) 2.20 (0.20) 14 – – – – –
NAA-NAAG 11.20 (0.41) 11.22 (0.36) 14 – – – – –
Cerebellum
Inositol 10.67 (2.19) 10.05 (1.51) 14 – – – – –
Glx 6.79 (0.65) 6.76 (0.75) 12 – – – – –
Cr 13.58 (1.73) 13.19 (1.28) 14 – – – – –
Cho 3.38 (0.53) 3.32 (0.36) 14 – – – – –
NAA-NAAG 13.02 (1.80) 12.98 (0.94) 14 – – – – –
Abbreviations: ACC, anterior cingulate cortex; Cho, glycerophosphocholine+phosphocholine; Cr, creatine+phosphocreatine; Glx, glutamate+glutamine; NAA-NAAG, 
N-acetylaspartate+N-acetylaspartylglutamate; PCC, posterior cingulate cortex.
Pair-wise comparisons between baseline and post-acute values were carried out for the PCC only, based on results from the ANOVA, which 
were significant only for this region. Comparisons were carried out using paired-samples Student’s t tests. Values are expressed as mean (SD) 
in millimolar concentration units. *P < .01; **P < .05; P FDR, FDR corrected P value.
Figure 2. Seed-to-voxel connectivity maps between the posterior cingulate cortex (PCC) seed (green circle) at MNI coordinates x = 0, y = -56, z = 28, and the rest of the 
brain. The top panels show statistically significant positive (hot colors) and negative (cold colors) correlations in the pre-ayahuasca and post-acute assessments. The 
bottom panels show the results of the second-level random effects analysis (post-acute vs. pre-intake). Only significant increases in connectivity were found, located 
in 2 main clusters: the anterior cingulate cortex (ACC) (left brain map) and the visual cortex (right brain map). In all statistical maps results are shown corrected for 
multiple comparisons at the cluster level (FWE < 0.05, z > 2.5, 20 contiguous voxels).
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Uncorrected maps can be found in the supplementary informa-
tion file (supplementary Figure 1)
As shown in the upper section of Figure 2 and the supple-
mentary file, prior to ayahuasca intake the BOLD time series 
in the PCC seed showed a pattern of positive correlations with 
brain regions known to participate in the DMN (Raichle et al., 
2001). On the other hand, the PCC seed showed negative cor-
relations with the ACC and other regions participating in the 
task-positive networks (TPNs) (Fox et  al., 2005). In the post-
acute phase, the negative correlation with the ACC was strongly 
reduced, suggesting a decrease in the orthogonality of BOLD 
activity between the PCC and the ACC.
The second-level random effects analysis confirmed the 
orthogonality decreases seen in the post-acute assessment 
maps. Brain areas demonstrating statistically significant 
changes in PCC seed-to-voxel connectivity are shown in the 
lower section of Figure  2 and are listed in Table  2. A  cluster 
of significantly increased connectivity (reduced anticorrela-
tion) was found in the ACC. A large significant cluster was also 
found over visual areas in the occipital lobe, where connectivity 
changed from negative to positive (see supplementary Figure 1). 
Additional clusters of increased connectivity were found in the 
pre- and post-central gyri and in the superior temporal gyrus 
and the insula. No areas of functional connectivity decrease 
were found in the second-level analysis.
Figure 3 shows the results of the second-level random effects 
statistical comparison between post-acute vs. pre-intake seed-
to-voxel connectivity for the dACC seed (dorsal ACC, x = 5, y = 14, 
z  =  42). Uncorrected maps for the first-level and second-level 
analyses can be found in supplementary Figure 2.
Significant connectivity increases were seen between the 
seed and voxels in the medial parietal cortex corresponding 
to the precuneus and posterior cingulate cortex. On the other 
hand, functional connectivity was decreased between the dACC 
Table 2. Brain Areas Showing Post-Ayahuasca Statistically Significant Changes in Seed-to-Voxel PCC Resting-State Functional Connectivity
Brain area BA MNI (x, y, z) Number of voxels Maximum t value
Areas showing increased connectivity
Cuneus (occipital lobe) 18/19 (2, -88, 24) 3824 6.80
Anterior cingulate gyrus 24/32 (-10, 8, 38) 605 6.80
Precentral gyrus/ postcentral gyrus 6/4 (-54, -2, 32) 1301 5.23
Superior temporal gyrus/ insula 22/13 (-32, -8, -2) 1401 5.10
Data shows results for the pair-wise comparison (post- vs. pre-intake) corrected for multiple comparisons at the cluster level (FWE < 0.05, z > 2.5, 20 contiguous 
voxels). The MNI coordinates indicate the location of the voxel with the maximum t value.
The PCC seed was located at (0, -56, 28) MNI coordinates. Data shows results of the pair-wise comparison (post- vs. pre-intake) corrected for multiple comparisons at 
the cluster level (FWE < 0.05, z > 2.5, 20 contiguous voxels). The MNI coordinates indicate the location of the voxel with the maximum t value. No areas were found 
showing significant decreases in connectivity with the PCC seed.
Figure 3. Statistical map showing the results of the second-level analysis (post- vs. pre-intake) of changes in connectivity between the dorsal anterior cingulate (dACC) 
seed (green circle) at MNI coordinates x = 5, y = 14, z = 42, and the rest of the brain. As shown in the top panel a significant increase in connectivity was found with vox-
els in the precuneus/posterior cingulate cortex. As shown in the bottom panel, significant decreases (cold colors) were found with voxels located in the cuneus (visual 
association cortex: BA 18 and 19). Results are shown corrected for multiple comparisons at the cluster level (FWE < 0.05, z > 2.5, 20 contiguous voxels).
Sampedro et al. | 705
seed and visual association areas (BA 18 and 19) in the occipital 
lobes. Cluster details are provided in Table 3.
Finally, Figure 4 shows the statistical maps corresponding to 
the second-level random effects statistical comparison of seed-
to-voxel changes between post-acute and pre-intake connectiv-
ity for the srACC seed (superior rostral ACC, x = 0, y = 15, z = 30). 
Cluster data are presented in Table 3, and uncorrected maps for 
the first-level and second-level analyses can be found in sup-
plementary Figure 3.
As shown therein, in the post-acute stage, this subregion of 
the ACC increased its connectivity with limbic structures within 
the right MTL, including areas of the parahippocampal gyrus, 
the hippocampus, and the amygdala. Increased connectiv-
ity was also found in the left parietal lobe and in the medial 
parietal lobe, over the posterior cingulate cortex. As shown in 
the first-level maps (supplementary Figure  3), this increase 
reflected a reduction of the anticorrelation between the ACC 
and the PCC. Finally, connectivity between the srACC and the 
visual cortex was significantly reduced in the post-acute stage. 
The inspection of the first-level maps shows that BOLD activity 
in this area changed from being positively to negatively coupled 
with that in the srACC.
Table 3. Brain Areas Showing Ayahuasca-Induced Statistically Significant Changes in Seed-to-Voxel Resting-State Functional Connectivity for 
the dACC Seed at MNI Coordinates (5, 14, 42) and the srACC Seed at (0, 15, 30)
Brain Area BA MNI (x, y, z) Number of voxels Maximum t value
dAAC seed (5, 14, 42)
Areas showing increased connectivity
Precuneus, posterior cingulate cortex 31 (-6, -42, 40) 864 3.76
Areas showing decreased connectivity
Cuneus (occipital lobe) 18/19 (28, -82, 0) 739 5.56
srACC seed (0, 15, 30)
Areas showing increased connectivity
Parahippocampal gyrus, hippocampus, amygdala (R) 35/28 (24, -18, -24) 660 6.04
Angular gyrus, inferior parietal lobule (L) 7/40/39 (-32, -74, 54) 633 6.02
Precuneus, posterior cingulate cortex (L&R) 31/7 (14, -54, 28) 1436 5.02
Areas showing decreased connectivity
Cuneus (occipital lobe) 18/19 (-2, -94, 6) 790 4.76
Abbreviations: dACC, dorsal anterior cingulate cortex; srACC, superior rostral anterior cingulate cortex.
Data shows results for the pair-wise comparison (post- vs. pre-intake) corrected for multiple comparisons at the cluster level (FWE < 0.05, z > 2.5, 20 contiguous 
voxels). The MNI coordinates indicate the location of the voxel with the maximum t value.
Figure 4. Statistical maps showing the results of the second-level analysis (post- vs. pre-intake) of changes in connectivity between the superior rostral anterior cingu-
late (srACC) seed (green circle) at MNI coordinates x = 0, y = 15, z = 30, and the rest of the brain. As shown in the top panel, decreases in connectivity (cold colors) were 
found with voxels located in the cuneus (visual cortex: BA 18 and 19). Increases in connectivity were found with 3 separate clusters (bottom panel): (a) the right medial 
temporal lobe (left brain map); (b) the precuneus and posterior cingulate cortex (center brain map); and (c) the left angular gyrus and left parietal lobule (right brain 
map). Results are shown corrected for multiple comparisons at the cluster level (FWE < 0.05, z > 2.5, 20 contiguous voxels).
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Mindfulness Measures
Figure 5 shows bar graphs of scores on those subscales of the 
FFMQ, EQ, and SC questionnaires that showed statistically sig-
nificant differences from pre-intake values in the post-acute 
assessment or at follow-up. Tabulated data for all subscales can 
be found in supplementary Tables 1 and 2.  As shown in sup-
plementary Table 1, participants already scored higher than the 
general population in several facets and higher than meditators 
in the 3 subscales of the SC questionnaire.
Despite high baseline values, further increases were 
observed in the post-acute assessment. The paired-samples 
comparison (post-acute vs. pre-ayahuasca) of the 5 subscales 
of the FFMQ showed statistically significant increases in scores 
on: nonjudging: [t(15) = -2.92, P = .011, P (FDR) = 0.021]; and non-
reacting: [t(15) = -2.61, P = .020, P (FDR) = 0.031]. The other 3 sub-
scales were not significantly modified. At follow-up 2 months 
later, the nonjudging score remained significantly higher than 
baseline: [t(13) = -2.22, P = .045], but this effect did not survive 
multiple comparisons correction using FDR (P = .495). Scores 
on the other 4 scales were not different from baseline values.
The EQ questionnaire also showed significant effects of aya-
huasca, with higher scores in the post-acute stage [t(15) = -3.58, 
P = .003, P (FDR) = .011]. At follow-up, scores were not different 
from baseline values.
The Mindsens composite score was significantly increased 
relative to baseline [t(15) = -3.63, P = .002, P (FDR) = .011]. Again, 
at follow-up, scores were not significantly different from those 
at baseline.
Analysis of scores on the SC questionnaire showed statisti-
cally significant increases [t(15)  =  -3.00, P = .009, P (FDR) = .020]. 
At follow-up 2  months later, values were not different from 
baseline.
Acute Subjective Effects
The analysis of scores on the different HRS subscales showed 
that ayahuasca intake led to significant psychoactive effects 
during the acute stage (supplementary Figure 4). The compara-
tive analysis with data from a previous laboratory study by our 
group (using independent samples Student’s t tests) showed 
significant differences from placebo for all subscales, except for 
volition. Scores in the present study on somaesthesia, affect, 
perception, volition, and intensity were not different from those 
we had obtained after a medium 0.75-mg DMT/kg ayahuasca 
dose (Valle et al., 2016). Only cognition was significantly differ-
ent, with higher scores obtained here: t(26) = 4.25, P (FDR) <.01.
Exploratory Correlation Analyses
We examined potential association between neurometabolic 
and functional connectivity changes, and scores on mindful-
ness measures and subjective effects. In all correlations, differ-
ence values (post-acute minus pre-ayahuasca) were used. For 
Figure 5. The graph bars shows mean scores on mindfulness measures that showed statistically significant post- vs. pre-ayahuasca intake changes. Data from n = 16 
participants at the pre- and post-acute assessments, and from n = 14 participants at follow-up 2 months later. FFMQ, Five Facets Mindfulness Questionnaire; EQ, Expe-
riences Questionnaire; MINDSENS, Mindsens composite index; SC, Self-Compassion Questionnaire. The error bars denote 1 standard error of mean. Significant differ-
ences in the statistical comparison (post-acute or follow-up vs. pre-intake) are denoted as *P < .05 after FDR correction. #Significance lost after FDR correction. Scores on 
nonsignificant subscales are provided in the supplementary information file.
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follow-up measures, the difference values from pre-ayahuasca 
scores were used. Scatter plots for the nonjudging subscale are 
shown in Figure 6. Additional scatter plots are included in sup-
plementary Figure 5.
Associations between neurometabolic and connectivity 
measures, and acute psychedelic effects
Scores on the cognition subscale of the HRS correlated with Cr 
decreases (n = 14; r = –0.735; r2 = 0.540; P = .003) and NAA-NAAG 
decreases in the PCC (n = 14; r = –0.622; r2 = 0.387; P = .018). No 
other significant correlations were found.
Associations between neurometabolic and connectivity 
measures, and post-acute mindfulness effects
Glx decreases in the PCC correlated with increases in the non-
judging FFMQ subscale (n = 12; r = –0.589; r2 = 0.506; P = .044). 
Increased srACC-PCC connectivity correlated with increases 
in the nonjudging (n = 16; r = 0.604; r2 = 0.365; P = .013) and Non-
Reacting (n = 16; r = 0.522; r2 = 0.272; P = .038) subscales of the 
FFMQ. Increased srACC-MTL connectivity similarly correlated 
with increases in the nonjudging (n = 16; r = 0.637; r2 = 0.406; 
P = .008) and nonreacting (n = 16; r = 0.656; r2 = 0.430; P = .006) 
subscales of the FFMQ, and with the SC score (n = 16; r = 0.514; 
r2 = 0.264; P = .042).
Association between neurometabolic and connectivity measures, 
and mindfulness effects at follow-up
Glx decreases in the PCC correlated with difference in the non-
judging subscale 2  months after baseline assessment (n = 11; 
r = –0.740; r2 = 0.548; P = .009). Positive correlations with sustained 
effects on nonjudging were also found for post-acute increases 
in srACC-PCC (n = 14; r = 0.584; r2 = 0.341; P = .028) and ACC-MTL 
(n = 14; r = 0.566; r2 = 0.320; P = .035) connectivity.
Discussion
Here we investigated the neural correlates of the psychedelic 
“after-glow” induced by ayahuasca in healthy volunteers. Using 
2 different MRI techniques, we evidenced significant neuromet-
abolic and functional connectivity changes hours after the acute 
effects of ayahuasca had disappeared. These modifications were 
associated with immediate changes in the psychological sphere 
Figure 6. Scatter plots showing significant correlations between difference scores at the post-acute and follow-up assessments (relative to baseline values) for the 
FFMQ nonjudging subscale and changes in neuroimaging measures (post-acute minus pre-intake). The top panels show the correlations with changes (Δ) in Glx 
(glutamate+glutamine) concentrations (millimolar) in the posterior cingulate cortex (PCC) voxel as measured using MRS. The middle panels show the correlations with 
changes in functional connectivity (Δ in z values) between the superior rostral anterior cingulate (srACC) seed and the precuneus/PCC cluster. The lower panels show 
the correlations with changes in functional connectivity (Δ in z values) between the srACC seed and the right medial temporal lobe (MTL) cluster. The left column 
shows correlations with FFMQ nonjudging difference scores in the post-acute assessment and the right column shows correlations with difference scores at follow-up. 
R and P values are reported in the main text.
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that were marginally maintained 2 months later. Our results 
replicate previous findings of enhanced mindfulness capacities, 
including increased “decentering,” and decreased judgmental 
and reactive attitudes during the post-acute phase of ayahuasca 
(Soler et al., 2016). Ayahuasca had the power to increase FFMQ, 
EQ, and Mindsens scores in individuals with already high base-
line scores (Soler et al., 2014a). We also found increases in self-
compassion, a previously unexplored facet in this context.
MRS showed neurometabolic changes in the PCC, a region 
rich in 5-HT2A receptors (Carhart-Harris et  al., 2012; Beliveau 
et al., 2016) and a target region of psychedelics (Palhano-Fontes 
et  al., 2015; Carhart-Harris et  al., 2016a; Valle et  al., 2016). Glx 
levels in the PCC were lower in the post-acute assessment com-
pared with baseline values, an effect that was however only 
marginally significant when corrected for multiple comparisons. 
We thus obtained partial evidence for the previously postulated 
involvement of glutamate neurotransmission in the effects of 
psychedelics (Kłodzinska et al., 2002; Moreno et al., 2011).
While we did not measure Glx levels during the acute psyche-
delic phase, our MRS findings are compatible with increased glu-
tamate levels during the acute stage. Cortical glutamate levels 
increase in periods of external perceptual stimulation or during 
active cognitive tasks, while they fall below baseline levels dur-
ing stimulation- or task-free periods (Mangia et al., 2007; Huang 
et al., 2015; Terhune et al., 2015). Also, acute psilocybin decreases 
brain aspartate (Preller et al., 2016), a neurotransmitter whose 
levels vary in an anticorrelated fashion with those of glutamate 
(Mangia et al., 2007). The post-acute Glx decreases in the PCC 
may result from increased excitatory activity during the acute 
phase. EEG and MEG studies in humans have shown a decrease 
of alpha oscillations, an inhibitory rhythm, in the parieto-occip-
ital cortex during the acute effects of psychedelics (Kometer 
et al., 2013; Carhart-Harris et al., 2016a; Valle et al., 2016).
The post-acute Glx reductions in the PCC are also consist-
ent with the observed reductions in Cr, NAA, and NAAG. Cr 
and N-acetyl compounds have been associated with metabolic 
activity, and NAAG has been directly linked to glutamater-
gic pathways (Rae, 2014). Additionally, the inverse correlation 
found between Cr and NAA-NAAG variations and scores on 
the HRS-Cognition subscale suggest a relationship between 
the intensity of acute effects and subsequent neurometabolic 
reductions. Neurometabolic changes may have contributed to 
the antidepressant effects reported for ayahuasca (Osório et al., 
2015; Sanches et al., 2016). Depressed patients show abnormally 
high glutamate levels in the parieto-occipital cortex (Bhagwagar 
et al., 2007). Glutamate reductions in these areas correlate with 
clinical improvement in depression (Abdallah et al., 2014).
The functional connectivity analysis also evidenced post-
acute changes. Activity in the PCC and associated areas within 
the DMN (Raichle et al., 2001) has been associated with the per-
sonal sense of “self.” Psychedelics acutely loosen the bounda-
ries of the “self” and increase the cross-talk between networks 
(Carhart-Harris et al., 2012, 2016a). Here, we found a post-acute 
increase in coupling between the PCC and a subregion of the 
ACC pertaining to the TPNs.
While DMN and TPN activity are typically anticorrelated (Fox 
et al., 2005), psilocybin and LSD acutely increase DMN-TPN con-
nectivity (Carhart-Harris et al., 2013), and general inter-network 
connectivity (Roseman et  al., 2014; Tagliazucchi et  al., 2016). 
Our results suggest that cross-talk lingers beyond the acute 
stage and contributes to the “after-glow,” reflected as enhanced 
mindfulness capacities. Increased DMN-TPN connectivity cor-
related with reduced judgmental processing, inner reactivity, 
and increased self-kindness, providing a neurobiological basis 
for these modifications. Conventional mindfulness training also 
increases DMN-TPN connectivity (Doll et al., 2015).
Visual areas showed increased coupling with the PCC but 
reduced with the ACC. This pattern suggests a greater interplay 
between internally generated visual information and sponta-
neous mind-wandering, and a reduction in cognitive control. 
These effects could explain increased phosphenes or “entop-
tic activity” persisting days after ayahuasca use (Frecska et al., 
2012). A previous neuroimaging study found increased activity 
in the visual cortex under ayahuasca (de Araujo et al., 2012).
The superior rostral ACC (srACC) seed also demonstrated 
increased functional coupling with parahippocampal, hip-
pocampal, and amygdalar areas of the MTL. Prior studies had 
identified these areas as targets of acute ayahuasca (Riba et al., 
2004, 2006; de Araujo et al., 2012). LSD acutely decreases fear rec-
ognition (Dolder et al., 2016), an effect mediated by the amyg-
dala, and psilocybin increases synchronization between the 
hippocampus and the ACC (Tagliazucchi et al., 2014).
Our data suggest that during the “after-glow” there is an 
enhanced interplay between the ACC, participating in execu-
tive tasks and in the binding of cognitive and emotional infor-
mation, with limbic structures with key roles in emotion and 
memory processes. This finding is particularly relevant in the 
interpretation of the antidepressant effects of ayahuasca. Other 
researchers have found abnormal interactions between the 
srACC and the amygdala in depressed patients, possibly indi-
cating decreased cognitive control over negative emotions (Fales 
et al., 2008).
Our data show for the first time that the modification 
induced by psychedelics on brain dynamics leads to changes 
in its neurometabolic, functional, and psychological balance 
beyond the acute stage. As previously reported (Griffiths et al., 
2011; Lebedev et  al., 2016), the post-acute phase in our study 
showed positive psychological effects, highlighting the paradox-
ical nature of psychedelics (Carhart-Harris et al., 2016c). While 
the acute inebriation shares features with psychosis (Schmid 
et al., 2015; Carhart-Harris et al., 2016c), psychedelics may lead 
to mid-term increases in psychological well-being. Increasing 
mindfulness capacities is clearly a desirable effect, especially in 
a psychotherapeutic context. Here post-acute scores were above 
values reported for meditators (Soler et al., 2014a), a population 
that also shows a pattern of decreased DMN-TPN anticorrela-
tion (Brewer et al., 2011; Froeliger et al., 2012). Considering that 
maladaptive ruminations in depression have been associated 
with greater DMN “dominance” over TPN activity (Hamilton 
et al., 2011), our results provide another interesting link between 
psychedelic-induced neural modifications and the therapeutic 
potential of ayahuasca.
The post-acute phase of the psychedelic experience had 
received little attention from modern neuroscience. Although 
investigators had postulated the capacity of psychedelics to 
modulate brain plasticity (Vollenweider and Kometer, 2010), 
most research had assessed mid- and long-term effects only 
from a psychological perspective. The changes in personal-
ity and life attitudes reported in the 1960s (Savage et al., 1966; 
Pahnke, 1969) have recently been replicated as increases in trait 
openness (Griffiths et al., 2006; Carhart-Harris et al., 2016c). Also, 
in a structural neuroimaging study of regular ayahuasca users, 
we found a cortical thinning of the PCC, the area showing neu-
rometabolic decreases in the present study. PCC thinning was 
inversely correlated with increased self-transcendence, a per-
sonality trait closely related to openness (Bouso et al., 2015).
Our MRS and connectivity data provide a biological basis for 
the therapeutic effects of ayahuasca (Osório et al., 2015; Sanches 
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et al., 2016). Its potential to influence brain dynamics at multiple 
levels suggests its usefulness to treat disorders that are highly 
refractory to therapeutic intervention. Its combined effect on 
the psychological and neural spheres may be particularly well 
suited to treat addiction disorders (Fernández and Fábregas, 
2014), where high impulsivity and self-centeredness coexist 
with alterations in brain function and structure (Vaquero et al., 
2016).
Our study has several limitations that need to be men-
tioned. We assessed a small sample of individuals before and 
after ayahuasca intake, with no control for placebo or time 
effects. The difficulties associated with Glx quantification 
allowed measurement in an even smaller sample. All partici-
pants had previous experience with ayahuasca, which may 
have biased our sample to individuals who usually experience 
positive effects after intake. Additionally, participants showed 
high baseline scores on several mindfulness facets. While 
this could be considered a limitation, it is also true that these 
capacities show “ceiling” effects and are difficult to increase 
in high scorers (Montero-Marin et  al., 2016). The correlation 
analysis should be considered exploratory and interpreted 
with caution. Finally, our study investigated only the sub-
acute stage of ayahuasca effects. The observed connectivity 
modifications cannot be interpreted as indicating persistent 
network changes. Future studies should consider using larger 
samples and double-blind, placebo-controlled designs. Also, 
the role of prior exposure to ayahuasca could be better estab-
lished by recruiting less experienced or even ayahuasca-naive 
individuals
To conclude, the present results indicate that ayahuasca 
and potentially other psychedelics induce neural modifications 
beyond the time frame of the acute inebriation. Neurometabolic 
decreases in the PCC and the increased inter-network connec-
tivity were associated with enhanced mindfulness facets. These 
associations provide hints to a potential biological basis for the 
therapeutic effects of ayahuasca.
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